Active Biotech: Interim report January - March 2017

(Thomson Reuters ONE) -




Laquinimod
* The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing
according to plan
* The study results from the pivotal clinical Phase 3 CONCERTO trial in
relapsing remitting multiple sclerosis (RRMS) are expected in the first half
of 2017
* The study results from the clinical Phase 2 ARPEGGIO trial, evaluating
laquinimod for the treatment of primary progressive multiple sclerosis
(PPMS), are expected in the second half of 2017
* Orphan Drug Designation granted for laquinimod for the treatment of
Huntington's disease by the US Food and Drug Administration (FDA)

ANYARA
* Project proceeding according to plan

Tasquinimod, paquinimod and SILC
* Out-licensing activities are continuing
* The European Patent Office has granted a patent application covering
tasquinimod for use in the treatment of multiple myeloma
* Orphan Drug Designation granted for tasquinimod for the treatment of
multiple myeloma by the US Food and Drug Administration (FDA)
* Product patent for SILC substances granted by the European Patent Office


Financial summary

SEK M Jan.-Mar.   Full-year

  2017 2016    2016
------------------------------------------------------------------------
Net sales 4.7   3.9     19.0

Operating loss -14.6 -16.1     -55.1

Loss after tax -15.8 -16.8     -59.6

Loss per share, before and after dilution (SEK) -0.16 -0.19   -0.65

Cash and cash equivalents (at close of period) 62.7  76.5     77.7




* Operations are progressing according to plan pending the Phase 3 results for

laquinimod in the first half of 2017

For further information, please contact:

  Tomas Leanderson, President and CEO Active Biotech AB
  Tel: +46 (0) 46 19 20 95 (Corp. Reg. No. 556223-9227)
  Box 724, SE-220 07 Lund
  Hans Kolam, CFO Tel: +46 (0)46-19 20 00
  Tel: +46 (0)46 19 20 44

The report is also available at www.activebiotech.com.

Active Biotech AB Interim report January - March 2017 :
http://hugin.info/1002/R/2099240/795362.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 27.04.2017 - 08:30 Uhr
Sprache: Deutsch
News-ID 538699
Anzahl Zeichen: 3069

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 134 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech: Interim report January - March 2017"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech